NeoPharm Submits Application For A Multicenter, Open-Label, Phase II Study Of LE-DT For Castrate Resistant Prostate Cancer

NeoPharm Submits Application For A Multicenter, Open-Label, Phase II Study Of LE-DT For Castrate Resistant Prostate Cancer
NeoPharm, Inc. (NASDAQ: NEOL) announced that it has submitted a Phase II protocol to the FDA for the study of liposome entrapped docetaxel (LE-DT), a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, in hormone refractory metastatic prostate cancer patients. "The preliminary results from our Phase I trial, which has not yet concluded, have been encouraging.

Required Online Course Provides Diabetes Education, Tools To Fight Obesity

There is another tool to manage diabetes and fight obesity the Internet, specifically, an online, university-based program on obesity and physical activity that can apply to diabetes education. The University of Houston department of health and human performance developed Public Health Issues in Physical Activity and Obesity (Kinesiology 1304) because of the prevalence of obesity and physical inactivity on campus. Complete news at...